Ocuphire Pharma EBIT 2010-2024 | IRD
Ocuphire Pharma ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
Ocuphire Pharma Annual EBIT (Millions of US $) |
2023 |
$-11 |
2022 |
$18 |
2021 |
$-23 |
2020 |
$-20 |
2019 |
$-4 |
2018 |
$-21 |
2017 |
$-17 |
2016 |
$-16 |
2015 |
$-18 |
2014 |
$-13 |
2013 |
$-8 |
2012 |
$-7 |
2011 |
$-16 |
2010 |
$-10 |
2009 |
$-6 |
Ocuphire Pharma Quarterly EBIT (Millions of US $) |
2024-06-30 |
$-8 |
2024-03-31 |
$-8 |
2023-12-31 |
$-5 |
2023-09-30 |
$6 |
2023-06-30 |
$-5 |
2023-03-31 |
$-6 |
2022-12-31 |
$34 |
2022-09-30 |
$-5 |
2022-06-30 |
$-5 |
2022-03-31 |
$-7 |
2021-12-31 |
$-6 |
2021-09-30 |
$-4 |
2021-06-30 |
$-7 |
2021-03-31 |
$-5 |
2020-12-31 |
$-14 |
2020-09-30 |
$-2 |
2020-06-30 |
$-1 |
2020-03-31 |
$-3 |
2019-12-31 |
$5 |
2019-09-30 |
$-2 |
2019-06-30 |
$-3 |
2019-03-31 |
$-4 |
2018-12-31 |
$-5 |
2018-09-30 |
$-5 |
2018-06-30 |
$-5 |
2018-03-31 |
$-6 |
2017-12-31 |
$-5 |
2017-09-30 |
$-4 |
2017-06-30 |
$-4 |
2017-03-31 |
$-4 |
2016-12-31 |
$-4 |
2016-09-30 |
$-4 |
2016-06-30 |
$-4 |
2016-03-31 |
$-5 |
2015-12-31 |
$-4 |
2015-09-30 |
$-5 |
2015-06-30 |
$-5 |
2015-03-31 |
$-4 |
2014-12-31 |
$-4 |
2014-09-30 |
$-3 |
2014-06-30 |
$-4 |
2014-03-31 |
$-3 |
2013-12-31 |
$-2 |
2013-09-30 |
$-2 |
2013-06-30 |
$-2 |
2013-03-31 |
$-2 |
2012-12-31 |
$-1 |
2012-09-30 |
$-2 |
2012-06-30 |
$-2 |
2012-03-31 |
$-2 |
2011-12-31 |
$-2 |
2011-09-30 |
$-3 |
2011-06-30 |
$-6 |
2011-03-31 |
$-4 |
2010-12-31 |
$-3 |
2010-09-30 |
$-2 |
2010-06-30 |
$-3 |
2010-03-31 |
$-2 |
2009-12-31 |
$-2 |
2009-09-30 |
$-1 |
2009-06-30 |
$-2 |
2009-03-31 |
$-1 |
Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|